148 related articles for article (PubMed ID: 32869346)
1. Mucosal chemokine CXCL17: What is known and not known.
Xiao S; Xie W; Zhou L
Scand J Immunol; 2021 Feb; 93(2):e12965. PubMed ID: 32869346
[TBL] [Abstract][Full Text] [Related]
2. CXCL17 is a mucosal chemokine elevated in idiopathic pulmonary fibrosis that exhibits broad antimicrobial activity.
Burkhardt AM; Tai KP; Flores-Guiterrez JP; Vilches-Cisneros N; Kamdar K; Barbosa-Quintana O; Valle-Rios R; Hevezi PA; Zuñiga J; Selman M; Ouellette AJ; Zlotnik A
J Immunol; 2012 Jun; 188(12):6399-406. PubMed ID: 22611239
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17.
Maravillas-Montero JL; Burkhardt AM; Hevezi PA; Carnevale CD; Smit MJ; Zlotnik A
J Immunol; 2015 Jan; 194(1):29-33. PubMed ID: 25411203
[TBL] [Abstract][Full Text] [Related]
4. What defines a chemokine? - The curious case of CXCL17.
Giblin SP; Pease JE
Cytokine; 2023 Aug; 168():156224. PubMed ID: 37210967
[TBL] [Abstract][Full Text] [Related]
5. CXCL17 Chemokine-Dependent Mobilization of CXCR8
Srivastava R; Hernández-Ruiz M; Khan AA; Fouladi MA; Kim GJ; Ly VT; Yamada T; Lam C; Sarain SAB; Boldbaatar U; Zlotnik A; Bahraoui E; BenMohamed L
J Immunol; 2018 Apr; 200(8):2915-2926. PubMed ID: 29549178
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review of chemokine CXC17 (VCC1) in cancer, infection, and inflammation.
Gowhari Shabgah A; Jadidi-Niaragh F; Ebrahimzadeh F; Mohammadi H; Askari E; Pahlavani N; Malekahmadi M; Ebrahimi Nik M; Gholizadeh Navashenaq J
Cell Biol Int; 2022 Oct; 46(10):1557-1570. PubMed ID: 35811438
[TBL] [Abstract][Full Text] [Related]
7. Mucosal Chemokines.
Hernández-Ruiz M; Zlotnik A
J Interferon Cytokine Res; 2017 Feb; 37(2):62-70. PubMed ID: 28207301
[TBL] [Abstract][Full Text] [Related]
8. CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells.
Oka T; Sugaya M; Takahashi N; Takahashi T; Shibata S; Miyagaki T; Asano Y; Sato S
J Immunol; 2017 May; 198(10):3897-3908. PubMed ID: 28389593
[TBL] [Abstract][Full Text] [Related]
9. CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor.
Lee WY; Wang CJ; Lin TY; Hsiao CL; Luo CW
Am J Physiol Endocrinol Metab; 2013 Jan; 304(1):E32-40. PubMed ID: 23115081
[TBL] [Abstract][Full Text] [Related]
10. CXCL17 is a major chemotactic factor for lung macrophages.
Burkhardt AM; Maravillas-Montero JL; Carnevale CD; Vilches-Cisneros N; Flores JP; Hevezi PA; Zlotnik A
J Immunol; 2014 Aug; 193(3):1468-74. PubMed ID: 24973458
[TBL] [Abstract][Full Text] [Related]
11. CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signaling.
Giblin SP; Ranawana S; Hassibi S; Birchenough HL; Mincham KT; Snelgrove RJ; Tsuchiya T; Kanegasaki S; Dyer D; Pease JE
Front Immunol; 2023; 14():1254697. PubMed ID: 37942327
[TBL] [Abstract][Full Text] [Related]
12. The protective and pathogenic roles of CXCL17 in human health and disease: Potential in respiratory medicine.
Choreño-Parra JA; Thirunavukkarasu S; Zúñiga J; Khader SA
Cytokine Growth Factor Rev; 2020 Jun; 53():53-62. PubMed ID: 32345516
[TBL] [Abstract][Full Text] [Related]
13. CXCL17-derived CD11b
Hsu YL; Yen MC; Chang WA; Tsai PH; Pan YC; Liao SH; Kuo PL
Breast Cancer Res; 2019 Feb; 21(1):23. PubMed ID: 30755260
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the Existence of a CXCL17 Receptor Distinct from GPR35.
Binti Mohd Amir NAS; Mackenzie AE; Jenkins L; Boustani K; Hillier MC; Tsuchiya T; Milligan G; Pease JE
J Immunol; 2018 Jul; 201(2):714-724. PubMed ID: 29875152
[TBL] [Abstract][Full Text] [Related]
15. GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17?
Park SJ; Lee SJ; Nam SY; Im DS
Br J Pharmacol; 2018 Jan; 175(1):154-161. PubMed ID: 29068046
[TBL] [Abstract][Full Text] [Related]
16. Intestinal guard: Human CXCL17 modulates protective response against mycotoxins and CXCL17-mimetic peptides development.
Sun C; Shen H; Cai H; Zhao Z; Gan G; Feng S; Chu P; Zeng M; Deng J; Ming F; Ma M; Jia J; He R; Cao D; Chen Z; Li J; Zhang L
Biochem Pharmacol; 2021 Jun; 188():114586. PubMed ID: 33932472
[TBL] [Abstract][Full Text] [Related]
17. The role and clinical significance of the CXCL17-CXCR8 (GPR35) axis in breast cancer.
Guo YJ; Zhou YJ; Yang XL; Shao ZM; Ou ZL
Biochem Biophys Res Commun; 2017 Nov; 493(3):1159-1167. PubMed ID: 28943434
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17.
Liu W; Xie X; Wu J
Cell Oncol (Dordr); 2020 Apr; 43(2):311-320. PubMed ID: 31832986
[TBL] [Abstract][Full Text] [Related]
19. CXCL17: The Black Sheep in the Chemokine Flock.
Denisov SS
Front Immunol; 2021; 12():712897. PubMed ID: 34335630
[No Abstract] [Full Text] [Related]
20. CXCL17 promotes cell metastasis and inhibits autophagy via the LKB1-AMPK pathway in hepatocellular carcinoma.
Wang L; Li H; Zhen Z; Ma X; Yu W; Zeng H; Li L
Gene; 2019 Mar; 690():129-136. PubMed ID: 30597237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
